tirzepatide fda news Lilly's weight-loss drug removed from FDA's shortage list FDA says the tirzepatide weight-loss

Irritation is uncommon but possible

We focus on personalized programs that look at the whole person, not just the BMI

We are committed to sustainability, and our product is free from harmful sulfates, parabens, and artificial colors

Semaglutide is an FDA-approved GLP-1 receptor agonist that is effective for chronic weight management in adults, especially those battling obesity or who have a weight-related condition

The shift isnt seismic yet, but momentum is building

ADA: Lilly makes its case for oral GLP-1 orforglipron A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control data in patients with type 2 diabetes, and a side-effect profile free of the liver toxicity that scuppered rival candidates from Pfizer